Humanized Mouse Model for Optimal Donor Selection in Transplantation
Daniel D.

1
Horuzsko ,

Ashwin

2
Ajith ,

Laura L.

3
Mulloy ,

2
Musa ,

A.
2
Horuzsko

Valia

1Philadelphia

3
Bravo-Egana ,

Imran

3
Gani ,

Anatolij

College of Osteopathic Medicine South Georgia, Moultrie, GA
Cancer Center, Augusta
3
University, United States, Medical College of Georgia, Augusta University, United States

ABSTRACT
The outcome of organ transplantation is largely dictated by selection of a well-matched
donor, which results in less chance of graft rejection. An allogeneic immune response is the
main immunological barrier for successful organ transplantation. Donor and recipient human
leukocyte antigen (HLA) mismatching diminishes outcomes after solid organ transplantation.
The current evaluation of HLA incompatibility does not provide information on the
immunogenicity of individual HLA mismatches and impact of non-HLA-related alloantigens,
especially in vivo. Here we demonstrate a new method for analysis of alloimmune
responsiveness between donor and recipient in vivo by introducing a humanized mouse
model. Using molecular, cellular, and genomic analyses, we demonstrated that a recipient’s
personalized humanized mouse provided the most sensitive assessment of allogeneic
responsiveness to potential donors. In our study, HLA typing provided a better recipientdonor match for one donor among two related donors. In contrast, assessment of an
allogeneic response by mixed lymphocyte reaction (MLR) was indistinguishable between
these donors. We determined that, in the recipient’s humanized mouse model, the donor
selected by HLA typing induced the strongest allogeneic response with markedly increased
allograft rejection markers, including activated cytotoxic Granzyme B-expressing CD8+ T
cells. Moreover, the same donor induced stronger upregulation of genes involved in the
allograft rejection pathway as determined by transcriptome analysis of isolated human
CD45+cells. Thus, the humanized mouse model determined the lowest degree of recipientdonor alloimmune response, allowing for better selection of donor and minimized
immunological risk of allograft rejection in organ transplantation. In addition, this approach
could be used to evaluate the level of alloresponse in allogeneic cell-based therapies that
include cell products derived from pluripotent embryonic stem cells or adult stem cells, both
undifferentiated and differentiated, all of which will produce allogeneic immune responses.

INTRODUCTION
Solid organ transplantation has been a life-saving procedure for thousands of patients
worldwide. Recent advances on improving donor-screening diagnostics have aimed at
identification of the most compatible donor for the transplant recipient to maximize allograft
survival. Current standards of donor selection rely on HLA typing and in vitro MLR, which
does not take into account the in vivo environment and recipient’s adaptive immune
response. Humanized mouse models are an appealing alternative that permits personalized
investigation of the immunocompatibility of potential donor tissues for the recipient human
immune system without putting patients at risk. By utilizing genomics, molecular and cellular
analyses of allogeneic immune response we analyze the efficiency of our novel humanized
mouse model to assess the donor-recipient compatibility and determined that it to be
significantly more sensitive than conventional screening methods.
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RESULTS
Analysis and Optimization of Humanization Phase in the Hu-NSGPBMC Mouse Model

Figure 2. Flow cytometry dot plots depict phenotype of the engrafted hCD45+ cells in the humanized mouse with gating for hCD3+,
hCD4+, and hCD8+ T cell populations. Characterization of hCD4 and hCD8+ T cells was expanded showing their respective CD62L
and CD25 expression. Graphical summary depicts frequency (%) of hCD4 and hCD8+ T cells as well as percent of CD62L+CD25and CD62L-CD25+ populations. N=5 mice per group. Data presented as mean ± SD. ***p <0.001, ****p<0.0001.

Hu-NSG-PBMC Mouse Model Exhibits Strong CD8+ T Cell-Mediated Allogeneic
Immune Response

Immunological graft rejection originates from alloimmune T cells derived from the host immune system. The
host alloimmune T cell response against donor-derived antigens such as HLA are much stronger in comparison
to classical immune responses against pathogen or self. This is due to the highly polymorphic nature of HLAs
combined with the presence of multiple HLA loci (HLA-A, B-class I antigens; HLA-DR, DQ, DP- class II
antigens). A diverse mismatch across the HLA alloantigens between the recipient and donor can elicit a robust
allogeneic immune response. These allospecific T cells of the host immune system can form activated cytotoxic
Granzyme B-expressing CD8+ T cells that are primarily responsible for graft tissue destruction and transplant
failure. Therefore, selection of the most immunocompatible donor for the recipient with the least amount of HLA
mismatches can maximize graft survival and reduce dependency on immunosuppressive treatments. In this
scenario, a well-matched related donor is the perfect candidate, allowing adequate time for investigating the
level of histocompatibility with the recipient. HLA typing and MLR are the long-time clinical standards for the
assessment of donor-recipient immunocompatibility in organ transplantation. Various studies have established
that an increased number of matched antigens and decreased number of mismatched antigens lead to
improved graft survival. However, HLA typing results are often confounded by the varying immunogenicity of the
different HLA loci. HLA-DR mismatches are known to contribute heavily to graft rejection, and HLA-A and B
matches are also crucial for graft acceptance. Meanwhile, HLA-DQ mismatch has no clinical significance unless
it is compounded by the presence of a DR mismatch; DP mismatches only become relevant during regraft
scenarios. Current donor organ allocation strategies consider mismatches at HLA-A, B, and DR to be equally
important. However, mounting evidence suggests that each HLA mismatch contributes differently to graft
survival; some HLA mismatches look more permissible than others. Benefits of dependence on HLA matching
are further diluted by other factors such as age; a younger donor age can compensate for the impact of HLA
mismatches. However, HLA typing does not consider the impact of non-HLA-related alloantigens. Growing
evidence suggests that as much as 38% of kidney allograft rejections are due to these non-HLA-related
alloantigens in comparison to 18 % caused by HLA mismatches. Thus, there is a need for additional methods to
assess immunocompatibility between recipient and donor. The most common and routinely used solution is
MLR. CFSE-based MLR assays enabled the phenotypic characterization of alloimmune T cells developed by
the recipient on stimulation by donor immune cells. However, the correlation between clinical outcomes and in
vitro functional MLR assays has been low due to the inherent inability of in vitro assays to replicate the in vivo
physiological environment. For example, unresponsive donor reactive cells commonly seen in MLR may arise
due to deletion or anergy, a phenomenon that is indistinguishable in an in vitro setting.

OBSERVATIONS
Our findings demonstrate:
1.) Hu-PBMC-NSG mouse show efficient engraftment with up to 60% of the engrafted CD8+ T cells being naïve T
cell (TN) phenotype being CD62L+CD25-

METHODS
HLA typing and MLR for histocompatibility. Special strain of immunodeficient mice, NSG
mice, subjected to irradiation (2Gy) and i.v injection of 8×10 peripheral blood mononuclear
cells (PBMCs) from transplant recipient. For allogeneic immune response, humanized
mouse received 3×10 PBMCs from unrelated donors(UD) or related donors(RD). Whole
genome transcriptome analysis and Real-Time PCR (RT-PCR) Transplant Rejection Array
was used.

SUMMARY

2.) The NSG-PBMC model showed a selective immune CD8+ T cell-based response on the UD allogeneic stimuli
while at the same time exhibited a tempered/controlled feedback to the RD challenge
Figure 3. Representative flow cytometry color plots depict gating strategy for CD25+ Granzyme B and Perforin-expressing activated
cytotoxic hCD8+ T cells in spleen of the humanized mouse for the Autologous, Related Donor (RD), and Unrelated Donor (UD)
challenge groups. Histogram shows expression of pro-inflammatory cytokines IL-2 (red line) and IFN-γ (blue line) amongst these
cytotoxic hCD8+T cells.

Transcriptome Analysis of Hu-PBMC-NSG vs. MLR Allogeneic Response

Humanized Mouse Model for Organ Transplantation

3.) The NSG-PBMC model showed an immune transcriptional profile
4.) MLR expresses minimal allogeneic response both cellular and transcriptional
5.) The Hu-PBMC-NSG model is significantly more sensitive than MLR

CONCLUSION
NSG-PBMC humanized mouse model was able to identify the related donor exhibiting minimal allogeneic response
to the recipient. This model is significantly more immunologically sensitive than conventional MLR and HLA typing for
selection of an immunocompatible donor for the transplant recipient.
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